Merck signs deal with Austria’s Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access to delivery technology.
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery
